Please confirm you are human (Sign Up for free to never see this)
← Back to Search
Autoimmunity Correlates With Tumor Regression In Patients With Metastatic Melanoma Treated With Anti-cytotoxic T-lymphocyte Antigen-4.
P. Attia, G. Phan, A. Maker, M. Robinson, M. Quezado, J. Yang, R. Sherry, S. Topalian, U. Kammula, R. Royal, N. Restifo, Leah R. Haworth, C. Levy, S. Mavroukakis, G. Nichol, M. Yellin, S. Rosenberg
Published 2005 · Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
PURPOSE Previously, we reported our experience treating 14 patients with metastatic melanoma using a fully human antibody to cytotoxic T-lymphocyte antigen-4 (anti-CTLA-4) in conjunction with peptide vaccination. We have now treated 56 patients to evaluate two different dose schedules of anti-CTLA-4 and to explore the relationship between autoimmunity and tumor regression. PATIENTS AND METHODS A total of 56 patients with progressive stage IV melanoma were enrolled onto the study. All had Karnofsky performance status > or = 60% with no prior history of autoimmunity. Twenty-nine patients received 3 mg/kg anti-CTLA-4 every 3 weeks, whereas 27 received 3 mg/kg as their initial dose with subsequent doses reduced to 1 mg/kg every 3 weeks. In both cohorts patients received concomitant vaccination with two modified HLA-A*0201-restricted peptides from the gp100 melanoma-associated antigen, gp100:209-217(210M) and gp100:280-288(288V). RESULTS Two patients achieved a complete response (ongoing at 30 and 31 months, respectively) and five patients achieved a partial response (durations of 4, 6, 25+, 26+, and 34+ months, respectively), for an overall objective response rate of 13%. Tumor regression was seen in lung, liver, brain, lymph nodes, and subcutaneous sites. Of 14 patients with grade 3/4 autoimmune toxicity, five (36%) experienced a clinical response compared with only two responses in the 42 patients (5%) with no autoimmune toxicity (P = .008). There were no significant differences in response rate or toxicity between the two dose schedules. CONCLUSION Administration of anti-CTLA-4 monoclonal antibody plus peptide vaccination can cause durable objective responses, which correlate with the induction of autoimmunity, in patients with metastatic melanoma.
This paper references
New Guidelines to Evaluate the Response to Treatment in Solid Tumors.
P. Therasse (2000)
CD4+CD25+ suppressor T cells: more questions than answers
E. Shevach (2002)
An essential role for Scurfin in CD4+CD25+ T regulatory cells
R. Khattri (2003)
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
G. Phan (2003)
Control of Regulatory T Cell Development by the Transcription Factor Foxp3
S. Hori (2003)
Allogeneic non-T spleen cells restore the responsiveness of normal T cell clones stimulated with antigen and chemically modified antigen-presenting cells.
M. Jenkins (1988)
Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
S. Rosenberg (1998)
A new member of the immunoglobulin superfamily—CTLA-4
J. Brunet (1987)
CTLA-4-Mediated inhibition of early events of T cell proliferation.
M. C. Brunner (1999)
Adoptive-cell-transfer therapy for the treatment of patients with cancer
M. Dudley (2003)
Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation
P. Linsley (1991)
Immunization of Patients with Metastatic Melanoma Using Both Class I- and Class II-Restricted Peptides from Melanoma-Associated Antigens
G. Phan (2003)
CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma.
A. Hurwitz (1998)
Cutting Edge: Transplantation Tolerance through Enhanced CTLA-4 Expression 1
C. Ariyan (2003)
CTLA-4 is a second receptor for the B cell activation antigen B7
P. Linsley (1991)
Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma.
Kristin M. Sanderson (2005)
Targeted CTLA-4 Engagement Induces CD4+CD25+CTLA-4high T Regulatory Cells with Target (Allo)antigen Specificity1
C. Vasu (2004)
CTLA‐4 regulates cell cycle progression during a primary immune response
R. Greenwald (2002)
Immunologic Self-Tolerance Maintained by Cd25+Cd4+Regulatory T Cells Constitutively Expressing Cytotoxic T Lymphocyte–Associated Antigen 4
T. Takahashi (2000)
CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells
M. Krummel (1996)
Enhancement of Antitumor Immunity by CTLA-4 Blockade
D. Leach (1996)
Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation
A. van Elsas (1999)
A cell culture model for T lymphocyte clonal anergy.
R. Schwartz (1990)
Cd4+Cd25+ Immune Regulatory Cells Are Required for Induction of Tolerance to Alloantigen via Costimulatory Blockade
P. Taylor (2001)
Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors.
P. Linsley (1994)
Prevention of autoimmune recurrence and rejection by adenovirus-mediated CTLA4Ig gene transfer to the pancreatic graft in BB rat.
F. Uchikoshi (1999)
CTLA-4 in autoimmune diseases – a general susceptibility gene to autoimmunity?
O. Kristiansen (2000)
Negative co-receptors on lymphocytes.
R. Greenwald (2002)
Identification and distribution of the costimulatory receptor CD28 in the mouse.
J. Gross (1992)
Re-establishing Peripheral Tolerance in the Absence of CTLA-4: Complementation by Wild-Type T Cells Points to an Indirect Role for CTLA-41
E. Tivol (2002)
CTLA-4 ligation blocks CD28-dependent T cell activation [published erratum appears in J Exp Med 1996 Jul 1;184(1):301]
T. Walunas (1996)
The CD28 ligand B7/BB1 provides costimulatory signal for alloactivation of CD4+ T cells
L. Koulova (1991)
CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy.
C. A. Chambers (2001)
CTLA-4 can function as a negative regulator of T cell activation.
T. Walunas (1994)
Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells.
Cynthia A Chambers (1997)
Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
H. A. Pass (1998)
CTLA-4: new insights into its biological function and use in tumor immunotherapy
J. Egen (2002)
T-cell regulation by CD28 and CTLA-4
M. Alegre (2001)
Characterization of CTLA-4 structure and expression on human T cells.
T. Lindsten (1993)
A Theory of Self-Nonself Discrimination
P. Bretscher (1970)
Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis.
M. Robinson (2004)
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
P. Waterhouse (1995)
This paper is referenced by
Clinical pharmacologic aspects of immune checkpoint inhibitors in cancer therapy
K. Kim (2016)
First world meeting of interdisciplinary melanoma/skin cancer centers
Monoclonal Antibody Therapy for Cancer
Christoph Rader (2011)
Diverse Mechanisms Regulate the Surface Expression of Immunotherapeutic Target CTLA-4
H. Schneider (2014)
Ipilimumab in patients with cancer and the management of dermatologic adverse events.
M. Lacouture (2014)
Toxicity as a result of immunostimulation by biologics
Elizabeth J Gribble (2007)
Management of metabolic adverse events of targeted therapies and immune checkpoint inhibitors in cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Farmacologia (SIF) multidisciplinary consensus position paper.
N. Silvestris (2020)
Blocking retinoic acid receptor-α enhances the efficacy of a dendritic cell vaccine against tumours by suppressing the induction of regulatory T cells
Karen C. Galvin (2013)
Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade
Stephanie G Downey (2007)
Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy
R. Danielli (2011)
RETINAL TOXICITIES OF CANCER THERAPY DRUGS: Biologics, Small Molecule Inhibitors, and Chemotherapies
C. Liu (2014)
Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab
C. Meyer (2013)
Systemic treatment of metastatic melanoma: New approaches
O. Hamid (2011)
The ipilimumab lesson in melanoma: achieving long-term survival.
J. Delyon (2015)
CTLA-4 Gene Exon-1 +49 A/G Polymorphism: Lack of Association with Autoimmune Disease in Patients with Common Variable Immune Deficiency
A. Knight (2006)
CTLA-4 dysregulation of self/tumor-reactive CD8+ T-cell function is CD4+ T-cell dependent.
L. Gattinoni (2006)
Out-of-Sequence Signal 3 Paralyzes Primary CD4(+) T-Cell-Dependent Immunity.
G. Sckisel (2015)
Immunotherapy for advanced melanoma: fulfilling the promise.
H. Gogas (2013)
Can benign lymphoid tissue changes in 18F-FDG PET/CT predict response to immunotherapy in metastatic melanoma?
C. Sachpekidis (2018)
Oncophage® (vitespen®) - Heat shock protein peptide complex 96-based vaccines in melanoma: How far we are, how far we can get?
Alessandra di Pietro (2009)
Cancer vaccines: up, down, … up again?
S. Neelapu (2009)
Melanoma vaccines: The problems of local immunosuppression.
M. Polak (2009)
Fall in thyroid stimulating hormone (TSH) may be an early marker of ipilimumab-induced hypophysitis
S. M. D. De Sousa (2018)
the Target Antigen Damaging the Brain despite Sharing Intracranial Tumor Cells without Immunotherapy Can Reject
Brian D Lichty (2010)
Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy)
Anna María (2011)
Eosinophilic count as a biomarker for prognosis of melanoma patients and its importance in the response to immunotherapy.
A. Moreira (2017)
Nebenwirkungsmanagement bei Immun‐Checkpoint‐Blockade durch CTLA‐4‐ und PD‐1‐Antikörper beim metastasierten Melanom – ein Update
Katharina C. Kaehler (2020)
Endocrine side-effects of anti-cancer drugs: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses.
F. Torino (2013)
Proposed mechanisms of action for prostate cancer vaccines
S. Geary (2013)
CTLA-4: Negative Regulator of the Immune Response and a Target for Cancer Therapy
U. Keilholz (2008)
Cancer immunotherapy: co‐stimulatory agonists and co‐inhibitory antagonists
K. Peggs (2009)
Endocrine side effects of cancer immunotherapy.
Priscilla Cukier (2017)See more